Conv. Plasma
Nigella Sativa
Peg.. Lambda

All HCQ studies
Meta analysis
Home COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 17% Improvement Relative Risk HCQ for COVID-19  Khoubnasabjafari et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 1,858 patients in Iran Fewer cases with HCQ (not stat. sig., p=0.59) Khoubnasabjafari et al., Postgraduate .., Jan 2021 Favors HCQ Favors control

Prevalence of COVID-19 in patients with rheumatoid arthritis (RA) already treated with hydroxychloroquine (HCQ) compared with HCQ-naive patients with RA: a multicentre cross-sectional study

Khoubnasabjafari et al., Postgraduate Medical Journal, doi:10.1136/postgradmedj-2020-139561
Jan 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Survey analysis of 1,858 RA patients in Iran, showing no significant difference in cases with HCQ prophylaxis.
risk of case, 16.7% lower, RR 0.83, p = 0.59, treatment 34 of 1,436 (2.4%), control 12 of 422 (2.8%), NNT 210.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Khoubnasabjafari et al., 13 Jan 2021, retrospective, Iran, peer-reviewed, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Prevalence of COVID-19 in patients with rheumatoid arthritis (RA) already treated with hydroxychloroquine (HCQ) compared with HCQ-­naive patients with RA: a multicentre cross-­ sectional study COVID-19 is becoming the most serious problem of human society after World War II. The general recommendations of WHO, which include wearing mask, social distancing, washing hands and so on, are a widely accepted approach to preventing the spread of the virus. With lack of effective treatment, prophylactic strategies have attracted the attention of healthcare providers. Chemoprophylaxis is one of these strategies. Several in vitro studies showed that antimalarial agents interfere with the proliferation of various viruses, including the severe acute respiratory syndrome coronavirus, by inhibiting virus/ cell fusion.1 However, the main challenge is translating the impact of in vitro models to clinics. Given the higher mortality of patients with COVID-19 with autoimmune diseases,2 we decided to investigate the efficacy of these medications by evaluating the incidence of COVID-19 in patients with rheumatoid arthritis (RA) already treated with hydroxychloroquine (HCQ) compared with HCQ-­naive patients with RA. In a multicentre cross-­ sectional study, patients with RA treated in the rheumatology clinics of the Tabriz University of Medical Sciences, Kashan University of Medical Sciences and Army Hospital of Tehran were recruited. For a period of 4 weeks from 19 August to 19 September 2020, data about symptoms suggestive of COVID-19 were obtained by telephone interview. Inclusion criteria were fulfilment of the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for RA, disease onset at age ≥16 and disease onset before the COVID-19 outbreak. Exclusion criteria were change or addition of new disease-­modifying antirheumatic drugs during the last 8 months, non-­adherence to medication, refusal to answer the questions and non-­response to Table 1 Demographic and clinical characteristics and medications of patients with RA enrolled in the study Characteristics and medications HCQ (n=1436) HCQ-­naive (n=422) P value Female (%) 1035 (72.1) 301 (71.3) 0.404 Age, mean±SD 51.1±12.3 50.6±13.1 0.123 RA disease duration, median (IQR) 54 (30–109) 66 (38–120) 0.193  Obesity (BMI >30) 253 (17.6) 63 (14.9) 0.252  Smoking 112 (7.8) 27 (6.4) 0.339  Diabetes 153 (10.7) 51 (12.1) 0.116  Hypertension 183 (12.7) 46 (10.9) 0.186  Pulmonary disease 33 (2.3) 13 (3.1) 0.127  Heart disease 36 (2.5) 10 (2.4) 0.592  Chronic kidney disease 13 (0.9) 5 (1.2) 0.271  Malignancies 19 (1.3) 3 (0.7) 0.419 Active RA disease 235 (16.4) 73 (17.3) 0.382  NSAIDs 159 (11.1) 51 (12.1) 0.326  Prednisolone 1057 (73.6) 326 (77.3) 0.059  Prednisolone dose, median (IQR) 5 (2.5–7.5) 5 (2.5–7.5) 0.106  Methotrexate 1106 (77.0) 318 (75.3) 0.328  Sulfasalazine 136 (9.5) 81 (19.2) 0.001  Leflunomide 219 (15.3) 55 (13.0) 0.222  Azathioprine 12 (0.9) 7 (1.7) 0.166  Calcineurin inhibitors 72 (0.5) 6 (1.4) 0.122  Biologics 40 (2.8) 15 (3.6) 0.314 COVID-19 (%) 34 (2.2) 12 (2.8) 0.344 Risk factors for COVID-19 (%) Medications (%) *p<0.05 considered significant. BMI, body mass index; HCQ, hydroxychloroquine; NSAIDs, non-­steroidal anti-­inflammatory drugs; RA, rheumatoid arthritis. Postgrad Med J Month 2021 Vol 0 No 0 three phone calls. Patients with..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop